{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:39:17Z","timestamp":1794310757041,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02190-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:37:31Z","timestamp":1748295451000},"page":"977-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Mirdametinib: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2190_CR1","doi-asserted-by":"crossref","unstructured":"Dillon M, Lopez A, Lin E, et al. Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers. Cancers (Basel). 2021;13(20):5059.","DOI":"10.3390\/cancers13205059"},{"issue":"4","key":"2190_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ajmg.c.32015","volume":"190","author":"M Zenker","year":"2022","unstructured":"Zenker M. Clinical overview on RASopathies. Am J Med Genet C Semin Med Genet. 2022;190(4):414\u201324.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2190_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/bs.acr.2021.07.007","volume":"153","author":"JF Longo","year":"2022","unstructured":"Longo JF, Carroll SL. The RASopathies: biology, genetics and therapeutic options. Adv Cancer Res. 2022;153:305\u201341.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"2190_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-023-10996-y","volume":"23","author":"AE Armstrong","year":"2023","unstructured":"Armstrong AE, Belzberg AJ, Crawford JR, et al. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer. 2023;23(1):1\u201312.","journal-title":"BMC Cancer"},{"issue":"11","key":"2190_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/neuonc\/noac165","volume":"24","author":"PMK De Blank","year":"2022","unstructured":"De Blank PMK, Gross AM, Akshintala S, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: clinical evidence and consensus. Neuro-oncol. 2022;24(11):1845\u201356.","journal-title":"Neuro-oncol"},{"issue":"15","key":"2190_CR6","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.18632\/oncotarget.2194","volume":"5","author":"YS Yap","year":"2014","unstructured":"Yap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited: from bench to bedside. Oncotarget. 2014;5(15):5873\u201392.","journal-title":"Oncotarget"},{"issue":"10","key":"2190_CR7","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1007\/s00381-024-06430-8","volume":"40","author":"C Kotch","year":"2024","unstructured":"Kotch C, de Blank P, Gutmann DH, et al. Low-grade glioma in children with neurofibromatosis type 1: surveillance, treatment indications, management, and future directions. Childs Nerv Syst. 2024;40(10):3241\u2013350.","journal-title":"Childs Nerv Syst"},{"key":"2190_CR8","unstructured":"SpringWorks Therapeutics, Inc. SpringWorks Therapeutics announces FDA approval of GOMEKLI\u2122 (mirdametinib) for the treatment of adult and pediatric patients with NF1-PN [media release]. 11 Feb 2025. https:\/\/springworkstx.com\/."},{"key":"2190_CR9","unstructured":"SpringWorks Therapeutics, Inc. GOMEKLI\u2122 (mirdametinib) capsules for oral use and tablets for oral suspension: US prescribing information. 2025. https:\/\/www.fda.gov\/. Accessed 13 Feb 2025."},{"key":"2190_CR10","unstructured":"US Food & Drug Administration. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection [media release]. 11 Feb 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic."},{"key":"2190_CR11","unstructured":"SpringWorks Therapeutics, Inc. SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of mirdametinib, extending patent protection into 2041 [media release]. 21 Jun 2021. http:\/\/www.springworkstx.com."},{"issue":"6","key":"2190_CR12","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-09-1883","volume":"16","author":"PM LoRusso","year":"2010","unstructured":"LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK\/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6):1924\u201337.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2190_CR13","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/pbc.25546","volume":"62","author":"E Jousma","year":"2015","unstructured":"Jousma E, Rizvi TA, Wu J, et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatr Blood Cancer. 2015;62(10):1709\u201316.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2190_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/JCO.20.02220","volume":"39","author":"BD Weiss","year":"2021","unstructured":"Weiss BD, Wolters PL, Plotkin SR, et al. NF106: a Neurofibromatosis Clinical Trials Consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas. J Clin Oncol. 2021;39(7):797\u2013806.","journal-title":"J Clin Oncol"},{"key":"2190_CR15","doi-asserted-by":"crossref","unstructured":"Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J Clin Oncol. 2025;43(6):716-729.","DOI":"10.1200\/JCO-24-02561"},{"issue":"Suppl 8","key":"2190_CR16","doi-asserted-by":"publisher","first-page":"viii113","DOI":"10.1093\/neuonc\/noae165.0437","volume":"26","author":"G Robinson","year":"2024","unstructured":"Robinson G, Vinitsky A, Bag A, et al. Results from the phase 1 and phase 1 expansion cohorts of SJ901: a phase 1\/2 trial of single-agent mirdametinib (PD-0325901) in children, adolescents, and young adults with low-grade glioma [abstract no. CTNI-70]. Neuro-oncol. 2024;26(Suppl 8):viii113.","journal-title":"Neuro-oncol"},{"key":"2190_CR17","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT04923126. 2025. https:\/\/clinicaltrials.gov\/. Accessed 10 Apr 2025."},{"key":"2190_CR18","doi-asserted-by":"crossref","unstructured":"Solomon B, Gao B, Subbiah V, et al. Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors [abstract no. CT033 plus presentation]. Cancer Res. 2023;83(8 Suppl).","DOI":"10.1158\/1538-7445.AM2023-CT033"}],"updated-by":[{"DOI":"10.1007\/s40265-025-02209-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02190-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02190-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:31:53Z","timestamp":1752139913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02190-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02190-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-025-02209-6","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access request","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-025-02209-6","URL":"https:\/\/doi.org\/10.1007\/s40265-025-02209-6","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}